Can Molecular Analysis be Tapped to Tackle Brain Cancer?

Compared to treatment advances for other types of cancer, progress in treating brain cancer has been frustratingly slow. Still, understanding the molecular changes that drive brain cancer remains “potentially transformative,” says Paul Mischel, a cancer biologist and neuropathologist at the Ludwig Institute for Cancer Research in San Diego.

Read More

FDA Approves First Targeted Therapeutic for BRCA-mutant Breast Cancer

On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain patients with metastatic, HER2-negative breast cancer. The FDA also granted marketing authorization for a test to identify those patients eligible to receive olaparib: patients with an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.

Read More

Fostering New Advances in Lung Cancer Research

A diverse group of about 220 physicians, patient advocates, and scientists in basic, translational, and clinical lung cancer research will convene in San Diego for an international conference organized by the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). The focus of the conference is “Lung Cancer Translational Science from the Bench to the Clinic.”

Read More

Experts Forecast Cancer Research and Treatment Advances in 2018

This past year has been a year of many “firsts” for the oncology community, with several revolutionary advances in the research and treatment of cancer, We asked experts in the fields of immunotherapy, precision medicine, and prevention and disparities research where the cancer research community is headed next and what major accomplishments we might expect in 2018 to take us closer to conquering cancer.

Read More

Reflections on a Year of Progress in Cancer Research

As 2017 draws to a close, I’ve been reflecting on another year in cancer research. As Chief Executive Officer of the American Association for Cancer Research, I am privileged to witness some of the most exciting discoveries that bring us closer to preventing and curing the complex set of diseases we call cancer.

Read More

A Young Chemical Biologist Forges a Career Path in Cancer Research

When we think about “cancer scientists,” we typically conjure images of physicians treating their patients or biologists analyzing cells under a microscope. But cancer scientists can be found in fields beyond medicine and biology, from physics to chemistry to mathematics.

Read More

Could Genomics Influence Prostate Cancer Treatment?

Prostate cancer is one of the most common cancers diagnosed in the United States. About one-third of men diagnosed with prostate cancer have a tumor that grows very slowly, making it very unlikely that the disease will progress to become a clinical problem. Characterizing new ways to identify these cancers is an area of active research investigation.

Read More

Biosimilars: Breaking Through to Cancer Treatment

A little-talked-about provision of the 2010 Patient Protection and Affordable Care Act designed to improve access to innovative medical therapies has recently borne fruit for the cancer community in the form of two new therapeutic options for a wide range of cancers—bevacizumab-awwb (Mvasi) and trastuzumab-dkst (Ogivri).

Read More

Holding Tobacco Companies Accountable for Deceptive Ads

The relationship between cigarette smoking and lung cancer was first brought to the public’s attention more than 50 years ago, when the U.S. Surgeon General’s report on “Smoking and Health” was published. However, tobacco companies are only now telling the truth about their deadly products, and only thanks to a 2006 court order that they spent more than a decade trying to overturn.

Read More